Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Benralizumab for Bronchiectasis
Recruiting1 awardPhase 3
Washington, District of Columbia
This trial tests if benralizumab can reduce lung flare-ups in adults with a specific lung condition involving high eosinophil levels. The medication works by lowering certain white blood cells that cause inflammation. Benralizumab helps improve lung function for patients with severe, uncontrolled asthma with eosinophilic inflammation.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service